These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8541725)

  • 1. Utility of a proliferation marker in distinguishing between benign naevocellular naevi and naevocellular naevus-like lesions with malignant properties.
    Kanter L; Blegen H; Wejde J; Lagerlöf B; Larsson O
    Melanoma Res; 1995 Oct; 5(5):345-50. PubMed ID: 8541725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucinous naevocellular naevi.
    Michal M
    Dermatology; 1994; 188(3):232-5. PubMed ID: 8186516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ultrastructure of dysplastic naevi: comparison with superficial spreading melanoma and common naevocellular naevi.
    Langer K; Rappersberger K; Steiner A; Konrad K; Wolff K
    Arch Dermatol Res; 1990; 282(6):353-62. PubMed ID: 2260880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferative activity of cutaneous melanocytic neoplasms defined by a proliferating cell nuclear antigen labelling index.
    Tokuda Y; Mukai K; Matsuno Y; Furuya S; Shimosato Y; Takasaki Y; Saida T; Ishihara K
    Arch Dermatol Res; 1992; 284(6):319-23. PubMed ID: 1363460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoplasmic beta-catenin is lacking in a subset of melanoma-associated naevi, but is detectable in naevus-associated melanomas: potential implications for melanoma tumorigenesis?
    De Panfilis G; Ferrari D; Santoro S; Ricci R; Lombardi M; Pedrazzi G; Pepe C; Cortelazzi C; Santini M
    Br J Dermatol; 2009 Mar; 160(3):600-8. PubMed ID: 19183173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic impact of nuclear DNA content and proliferative activity in benign and malignant melanocytic lesions.
    Steinbeck ZR; Heselmeyer KM; Gerlach B; Björnhagen V; Auer GU
    Melanoma Res; 1996 Feb; 6(1):37-43. PubMed ID: 8640068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface microscopy of naevi and melanomas--clues to melanoma.
    Nilles M; Boedeker RH; Schill WB
    Br J Dermatol; 1994 Mar; 130(3):349-55. PubMed ID: 8148277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological demarcation of lateral borders: an unsupportable criterion for distinguishing malignant melanoma from Spitz naevus and compound naevus.
    Okun MR
    Histopathology; 1998 Aug; 33(2):158-62. PubMed ID: 9762549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
    Fröhlich E; Mack AF; Garbe C; Klessen C
    Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
    Skender-Kalnenas TM; English DR; Heenan PJ
    J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VS38 immunostaining in melanocytic lesions.
    Shanks JH; Banerjee SS
    J Clin Pathol; 1996 Mar; 49(3):205-7. PubMed ID: 8675729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type VII collagen antibody LH 7.2 identifies basement membrane characteristics of thin malignant melanomas.
    Kirkham N; Price ML; Gibson B; Leigh IM; Coburn P; Darley CR
    J Pathol; 1989 Mar; 157(3):243-7. PubMed ID: 2647941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of proliferative activity as assessed by proliferating cell nuclear antigen (PCNA) and Ki-67 monoclonal antibodies in melanocytic skin lesions. A quantitative immunohistochemical study.
    Rieger E; Hofmann-Wellenhof R; Soyer HP; Kofler R; Cerroni L; Smolle J; Kerl H
    J Cutan Pathol; 1993 Jun; 20(3):229-36. PubMed ID: 8103531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.
    Björnhagen V; Bonfoco E; Brahme EM; Lindholm J; Auer G
    Am J Dermatopathol; 1994 Dec; 16(6):615-23. PubMed ID: 7864299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 expression is rare in cutaneous melanomas.
    Saenz-Santamaría MC; McNutt NS; Bogdany JK; Shea CR
    Am J Dermatopathol; 1995 Aug; 17(4):344-9. PubMed ID: 8600797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psammomatous malignant melanoma arising in an intradermal naevus.
    Monteagudo C; Ferrández A; González-Devesa M; Llombart-Bosch A
    Histopathology; 2001 Nov; 39(5):493-7. PubMed ID: 11737307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanocytic activation in HIV-1 disease: HMB-45 staining in common acquired nevi. Military Medical Consortium for the Advancement of Retroviral Research.
    Smith KJ; Skelton HG; Heimer W; Baxter D; Angritt P; Frisman D; Wagner KF
    J Am Acad Dermatol; 1993 Oct; 29(4):539-44. PubMed ID: 7691905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferative activity of keratinocytes correlates with that of melanocytes in naevi and melanomas.
    Tronnier M; Kämmerer R; Wolff HH
    Arch Dermatol Res; 1995; 287(5):509-11. PubMed ID: 7625864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.